大阪府立公衆衛生研究所薬事指導部 平成10年度行政試験実施品目一覧表(理化学試験)

	成分名	試験項目	測定方法	剤型
大工業製	リン酸リボンラドンナトリウム 塩酸でリドキシン ニロチン酸アミド リボンラビン がメコルメルチアミン アメコルビン酸 群酸 d ー α ー ト コフェロール は次フォチアミン は次フォチアミン は次数 d ー α ー ト コフェロール は次フォチアミン	有効成分の定量 重量偏差試験 崩壊試験	HPLC (ODS) 滴定 (直接滴定) HPLC (Phenyl)	フィルムコーティング 糖太館 素館 大学でル剤 題粒剤 硬カプセル剤 硬カプセル剤
H2遮断薬	指数ロキサチジンアセタートンメチジンフェチジンフェーチジンフェーチジンニザチジンニザチジン	有効成分の定量 重量偏差試験 崩壊試験	HPLC (CN) HPLC (ODS)	硬カプセル剤 フィルムコーティング錠 細粒剤
局方製剤	塩酸エチレフリン 塩酸ヒドララジン	有効成分の定量 重量偏差試験 崩壊試験 溶出試験	吸光度	素錠糖衣錠
歯科用医薬品 (消毒剤)	) 植化ベンザルコニウム グルコン酸クロルヘキンジン グルタルアルデにド 植化ベンゼトニウム ヨウ素 ロウ化カリウム フェノール チモール d1ーメントール が形式 は 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	有効成分の定量	滴定 (直接滴定) 吸光度 HPLC (ODS) GC	被剤
解熱鎮痛消炎剤	<u>(大田価米段) ドップカンプロフェナクナトリウム</u> アセトアミノフェン インドメタシンファルネシル	有効成分の定量 重量偏差試験 崩壊試験	HPLC (ODS) 吸光度 滴定 (直接滴定)	<b>硬カプセル剤</b> 散剤 軟カプセル剤

細粒剤 フィルムコーティング錠 素錠	素錠 硬カプセル剤 細粒剤	素錠	フィルムコーティング錠 細粒剤	上薬	注射剤		化粧水	香水
HPLC (phenyl)	吸光度 HPLC (ODS)	- HPLC (C8) 吸光度 HPLC (ODS)	滴定 (直接滴定)	日局生薬試験法	吸光度 HPLC (ODS)		HPLC (ODS)	HPLC (ODS) 吸光度
容田試験	有効成分の定量 重量偏差試験 崩壊試験	有効成分の定量 重量偏差試験 崩壊試験	有効成分の定量 崩壊試験	精油含量	有効成分の定量	有効成分の定量 経時変化試験 含量均一性試験	配合上限成分の確認表示指定成分の確認	表示指定成分の確認 配合禁止成分の確認 溶出物試験 強熱残分試験
フェナセチンマレインタレインをレインをプログルメルンスルルリンインドメタシンアンファインドメタシンアンファーナクナトリウムアナメタシン	塩酸プロムヘキツン 塩酸アンブロキンール 1-カルボツステイン	イプリフラボン メシル酸カモスタット	塩酸アマンタジン	ケイアサインン アナインン バナケンション カイギョウ	リン概ピリドキサールメロバラミンコバシミア ロバトミド ヒドロキンコバラミン ツァー	<u>抱水クロラール</u> 塩酸ブロムヘキシン 硫酸サルブタモール アナノロール 酒石酸メトプロロール	酢酸トコフェロール セチルアルコール ステアリルアルコール トコフェロール	パラベン類 ホルムアルデヒド
	去液剤	代謝性医薬品	抗パーキンンン剤	1	ビタミン含有注射薬	その他の医療用医薬品	化粧品	化粧品医療用具

<b>硬カプセル剤</b> 糖衣錠 素錠	液剤
吸光度 HPLC (ODS)	紫外吸収スペクトル 赤外吸収スペクトル HPLC (ODS)
<b>黎</b> 田·沙	確認・定量
インドメタンソ 基酸クロアプロ~ジン メサアドふ プレドニゾロン インニアジド 植酸プロガインアルド クロアジアがポキシド トチェアトレア ドチェアトフト ドチェアトファ	タウリン
内用固形製剤	内用液剤

7

60 International Congress of FIP. Vienna 2000.8.28-31 (Austria Center)

The study of structuring mutual network of pharmaceutical affairs among national institutes and local institutes.

Mumio ISHIBASHI, Naoko KANIWA, Michiharu NAKANO <sup>1</sup>, Kotoko NAKATA, Yoshiyuki SAWABE <sup>2</sup>, Tsuyoshi TANIMOTO. National Institute of Health Sciences "198-8501, Japan", Hokkaido Institute of Public Health <sup>1</sup> and Osaka Prefectural Institute of Public Health<sup>2</sup>

The purpose of the institutes: There are national institutes (National Institute of Health and National Institute of Infectious Disease), which test the quality of medicine at the request of the Ministry of Health and Welfare, and 59 district institutes, which do the same test at the request of local government in Japan. Then we studied for structuring mutual information trade network between national institute and district institute or among the district institutes. This study aimed to unify information from these institutes, and to secure the quality of medicine more organically, more rapidly, more efficiency and without regional differences.

Method: 49 institutes (National Institutes and so on) participated in structuring the network. We studied the management of network, availability of information should be provided. And we also studied the usefulness of network concerning the detection of the case against pharmaceutical affairs low, maintenance of secret, and care for the ethics and so on.

Results: The network were utilized these network for supplying the method of analysis, standard of spectrum analysis. Then we could confirm the usefulness of mutual network to ensure the quality of medicine. And intercommunity of information could decrease the area gap in the matter of testing the quality of medicine. As the result of the sharing the knowledge on network, the effect of decreasing the public healthy injury by defective or injurious medicine was confirmed. Furthermore sharing information decrease dissatisfaction and insufficiency

people had in national or public institutes. After this in view of these outcome, we promote the more available usage of network. We would like to accelerate the value of network and use it to restrain people from the damage of defective or injurious by interchanging more frequently and up grading the data base moreover.

# The Study of Structuring Mutual Network of Pharmaceutical Affairs Among National Institutes and Local Institutes

Mumio ISHIBASHI, Naoko KANIWA, Michiharu NAKANO\*, Kotoko NAKATA, Yoshiyuki SAWABE\*\* and Tsuyoshi TANIMOTO National Institute of Health Sciences (Japan), Hokkaido Institute of Public Health\*

### A: Purpose of the study

This study aimed at prevention of the distribution of unjust or defective drugs more quickly and minimization of the healthy damage of people to receive from unjust or defective drugs in Japan.

### B: Achievement method for the purpose

In Japan, there are national research institutes (3 institutes) examining quality of drugs by a request of the Ministry of Health and Welfare and district institutes (about 70 instutes) to examine similar quality research by a request of a local government.

Then we build a mutual information exchange network between these national research institutes and district research institutes or a district research institute and district research institutes. And we attain the purpose by unifying the information that these institutes have.

## C: The formal course of information releases between public offices

Information releases about the detection of unjust or defective drugs in Japan are done like next by dispatch of documents.

District institute for health A  $\rightarrow$  prefectural office A(Pharmaceutical Affairs Div.)  $\rightarrow$  Ministry of Health and Welfare (Pharmaceutical safety bureau)  $\rightarrow$   $\rightarrow$   $\rightarrow$   $\rightarrow$   $\rightarrow$   $\rightarrow$   $\rightarrow$   $\rightarrow$   $\rightarrow$ 

- → prefectural office B → district institute for health B
- → National institute for health
- → prefectural office C → district institute for health C

### D: The establishment of informal information release course

We utilize a network and install release course of informal information. By this we exchange information quickly and do quick exclusion of unjust or defective drugs.

The district institute for health A (researcher)	
→ district institute for health B ( researcher)	
→ district institute for health C ( researcher)	
→ district institute for health D (researcher)	
→ National institute for health (researcher)	
→ Ministry of Health and Welfare (medicine	security bureau)
-> prefectural office A (pharmaceutical affairs	dev.) (official)
The following is not affiliated to the	• • •
→ prefectural office B (pharmaceutical affairs	dev.) (official)
→ prefectural office C (pharmaceutical affairs	dev.) (official)

# E: Precondition of establishment of informal information release course

- 1: The network is administered with closed and a home page is protected by a password.
- 2: A researcher belonging to the network communicates information to other researchers with e-mails when they detected unjust or defective drugs and doubted drugs.
- 3: It is assumed that contents of information are informal. We use formal information releases course between formal government offices as a formal release of information.
- 4: Contents of information are based on the result of early examination. Thus because contents of information may be lacking in accuracy, we protect obligation of keeping secrecy of a public employee strictly.
- 5: When release of information became necessary, we cope mainly on a sender of information adequately.
- 6: The others, we change information such as examination technology, information exchange about reference standard and registration of the results of examination necessary for drug application regulation.

# F: The problems that occurred on the occasion of network administration

administration
O Resistance of local government for informal information offering and
information exchange
O Lack of budget for a network(LAN) in district institute for health and
lack of understanding of a local government for it
O Difference of level and recognition exist in district institute for health
about information management (a habit of secret and so on)
A burden of network manager with work to be related to a network
O Information release procedure

G: The results of network access  © The following information exchange that utilized a mailing list
O Information exchange about the test method, reference standard and the
<ul> <li>○ Exchange of know-how about the procedure of GMP inspection</li> <li>○ Submitting of problems that people in charge of examination has, and answers to them from the practicians experienced examination</li> <li>○ Information providing about an test method of Pharmacopeia from national research institute</li> <li>○ An opinion of district institute for health about the official test method</li> <li>○ Exchange of test result of market product that accumulated at each district institute for health</li> </ul>
<ul> <li>The following information exchange by notice board</li> <li>Among information changed in the above, the information with the significance that should be carried is laid on a notice board.</li> <li>(writing is impossible from the outside on the notice board)</li> <li>Writing up the matter to think that participants want to present on a notice board</li> <li>(members write on it freely)</li> </ul>
H: Net rate and a mailing list of national research institute and district institute for health
Net rate: It is 63 institutes among national and district research 73 institutes. (non-engage institutes are during preparation of their LAN)
A mailing list: About 250 people
I: Effect for exclusion from a market of unjust or defective drugs got by
Net  O By information exchange, we specified chemical compounds (include drugs) mixed falsely in traditional drugs and healthy food more quickly and removed them more quickly from the market.  O By detection information of defective drugs from one district institute for health, other district institute for health could remove the similar defective drugs without area disparity from the market quickly.

O By virtue of exchange of information about the test method, the

know-how of the test method and reference standard, it became more